1
|
Sehouli J, Oskay-Öczelik G, Zocholl D, Klemt AS, Bangemann N, Albrecht O, Strittmatter HJ, Wimberger P, Kaczerowsky A, Lorenz R, Ruhwedel W, Fehm T, Zahn A, Tome O, Markert M, Hager D, Zorr A, Keller M, Rittmeister H, Grabowski J. 1573P Developing a patient-related predictive model for the occurrence of CINV (NOGGO-EMRISK trial): Prospective, multicentre study in Germany. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Eichelroth M, Bangemann N. Schilddrüsenmetastase als Primärmanifestation eines Mammakarzinoms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1714536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
3
|
Ohlinger R, Alwafei Z, Thill M, Baumann K, Pursche T, Bangemann N, Mett R, Faridi A, Strittmatter HJ, Kiechle M, Paepke S. Präpektorale Implantateinlage in der plastisch-rekonstruktiven Mammachirurgie unter Verwendung des TiLOOP®BraPocket. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- R Ohlinger
- Universitätsmedizin Greifswald, Klinik und Poliklinik Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - Z Alwafei
- Universitätsmedizin Greifswald, Klinik und Poliklinik Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - M Thill
- Agaplesion Markus Krankenhaus, Frankfurt am Main, Deutschland
| | - K Baumann
- UKSH Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - T Pursche
- UKSH Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - N Bangemann
- Klinik für Gynäkologie mit Brustzentrum der Charité, Berlin, Deutschland
| | - R Mett
- HELIOS Klinikum Schwerin, Klinik für Plastische und Ästhetische Chirurgie, Schwerin, Deutschland
| | - A Faridi
- Vivantes Brustzentrum Am Urban, Berlin, Deutschland
| | | | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Paepke
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
4
|
Kiver V, Gambara G, Jurmeister P, Schweiger C, Fuchs K, Gorea O, Burock S, Liedtke C, Karsten M, Bangemann N, Kußmaul J, Hoffmann J, Regenbrecht C, Denkert C, Keilholz U, Blohmer JU. Erfolgreiche Etablierung von präklinischen Brustkrebsmodellen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- V Kiver
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
- Charité Comprehensive Cancer Center, Berlin, Deutschland
| | - G Gambara
- Charité Comprehensive Cancer Center, Berlin, Deutschland
- Deutsches Konsortium für translationale Krebsforschung, Berlin, Deutschland
- Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
| | - P Jurmeister
- Charité Comprehensive Cancer Center, Berlin, Deutschland
- Charité – Universitätsmedizin Berlin, Institut für Pathologie, Berlin, Deutschland
| | - C Schweiger
- Charité Comprehensive Cancer Center, Berlin, Deutschland
- Deutsches Konsortium für translationale Krebsforschung, Berlin, Deutschland
- Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
| | - K Fuchs
- Deutsches Konsortium für translationale Krebsforschung, Berlin, Deutschland
- Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
| | - O Gorea
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
- Charité Comprehensive Cancer Center, Berlin, Deutschland
| | - S Burock
- Charité Comprehensive Cancer Center, Berlin, Deutschland
| | - C Liedtke
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - M Karsten
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - N Bangemann
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - J Kußmaul
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - J Hoffmann
- Experimental Pharmacology &Oncology Berlin GmbH-Buch, Berlin, Deutschland
| | - C Regenbrecht
- cpo – cellular phenomics& oncology Berlin-Buch GmbH, Berlin, Deutschland
| | - C Denkert
- Deutsches Konsortium für translationale Krebsforschung, Berlin, Deutschland
- Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
- Charité – Universitätsmedizin Berlin, Institut für Pathologie, Berlin, Deutschland
| | - U Keilholz
- Charité Comprehensive Cancer Center, Berlin, Deutschland
- Deutsches Konsortium für translationale Krebsforschung, Berlin, Deutschland
- Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
| | - JU Blohmer
- Charité – Universitätsmedizin Berlin, Campus Mitte, Gynäkologie mit Brustzentrum, Berlin, Deutschland
| |
Collapse
|
5
|
Pullankavumkal J, Vasiljeva J, Lanowska M, Blohmer JU, Bangemann N. Autoimmunnephritis nach Pembrolizumabtherapie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Pullankavumkal
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - J Vasiljeva
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - M Lanowska
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - JU Blohmer
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - N Bangemann
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| |
Collapse
|
6
|
Lauterbach LK, Mangler M, Blohmer JU, Grittner U, Bangemann N. Lebensqualität nach prophylaktischer Mastektomie bei nachgewiesener BRCA-Mutation im Vergleich zu einer nicht operierten Kontrollgruppe. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- LK Lauterbach
- Klinik für Frauenheilkunde und Geburtshilfe, St. Anna- Hospital, Herne, Deutschland
| | - M Mangler
- Klinik für Gynäkologie und Geburtsmedizin, Auguste-Viktoria-Klinikum, Berlin, Deutschland
| | - JU Blohmer
- Klinik für Gynäkologie mit Brustzentrum, Charité- Universitätsmedizin, Berlin, Deutschland
| | - U Grittner
- Institut für Biometrie und Klinische Epidemiologie, Charité- Universitätsmedizin, Berlin, Deutschland
| | - N Bangemann
- Klinik für Gynäkologie mit Brustzentrum, Charité- Universitätsmedizin, Berlin, Deutschland
| |
Collapse
|
7
|
Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, Pelz E, Kates RE, Wuerstlein R, Kreipe HH, Harbeck N. Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathological complete response (pCR) is associated with improved prognosis in TNBC, but optimal chemotherapy remains unclear. Use of weekly nab- paclitaxel (Nab-Pac) vs. conventional paclitaxel and also addition of carboplatinum(Carbo) to anthracycline-taxane(A/T) containing chemotherapy results in significantly higher pCR rates in TNBC with unclear impact on survival and increased toxicity.
The ADAPT study seeks to compare Carbo vs. gemcitabine(Gem) added to nab- paclitaxel as a short 12-week A-free regimen. It also assesses efficacy in early responders vs. non-responders by 3-week proliferation and/or imaging response.
Methods: ADAPT TN compares 12-week neoadjuvant regimens: Carbo vs. Gem combined with Nab-Pac and aims to identify early-response markers for pCR (yPN0 and ypT0/is). TNBC patients (centrally confirmed ER/PR <1%, HER2 neg.), cT1c- cT4c, cN0/+ were randomized to arm A (Nab-Pac 125/Gem 1000 d1,8 q3w) vs. B (Nab-Pac 125/Carbo AUC2 d1,8 q3w). Randomization was stratified by center and nodal status. The trial is powered for pCR comparison by therapy arm and by presence vs. absence of early response markers. Pre-planned interim analysis aimed to identify a dynamic biomarker, e.g. drop of 3-week Ki-67, and to validate trial assumptions.
Results: 336 patients were enrolled from 47 centers between 06/13-02/15 (n=182 ArmA: Nab-Pac/Gem and n=154 ArmB: Nab-Pac/Carbo). 90% and 95% completed therapy according to protocol respectively (n.s.). Median age was 50y. At baseline: A/B: 73% and 74%% had G3 tumors, median Ki-67 of 70% and 75%; 62.6% and 62.9%% had cT2-4c tumors, pN0 status prior to chemotherapy was confirmed in 50.5% and 50%, respectively.
pCR (ypT0/is/ypN0) was A: 28.7% and B: 45.9% (p<0.001). Total pCR (ypT0/ypN0) was A: 25.8% and B: 45.2% respectively (p <0.001).
Nab/Gem arm was associated with significantly higher frequency of dose reductions (20.6% vs. 11.9% (p=0.03), treatment related SAE's (13% vs. 5%, p=0.02), grade 3-4 infections (6.1% vs. 1.3%, p=0.04) and ALAT elevations (11.7 vs. 3.3%, p=0.01) compared to the Nab-Carbo arm.
Within the planned interim analysis (n=130: A/B: 69/61), baseline Ki-67 (Nab- Pac/Carbo arm), age>50 years, and low cellularity (<500 tumor cells and/or Ki-67≤10% in the 3-week biopsy) (Nab-Pac/Gem arm) were positively associated with pCR by logistic regression analysis (separately by therapy arm). In all patients, therapy arm itself was significant for pCR.
Validation of responder definitions for the whole study will be presented at the meeting.
Conclusions:
This is the first large randomized study comparing two short 12-week anthracycline- free regimens in unselected TNBC. Our results suggest superior efficacy and excellent toxicity of Nab-Pac/Carbo vs. Gem. Longer A/T-Carbo containing regimens render quite comparable pCR rates, thus overtreatment by 4xEC in unselected TNBC may be present in some patients. Early response criteria seem to differ according to regimen; their assessment may be impaired by substantial tumor necrosis already after the first therapy cycle.
Citation Format: Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, Pelz E, Kates RE, Wuerstlein R, Kreipe HH, Harbeck N. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-13-01.
Collapse
Affiliation(s)
- O Gluz
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - U Nitz
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - C Liedtke
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - M Christgen
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - K Sotlar
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - EM Grischke
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - H Forstbauer
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - M Braun
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - M Warm
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - J Hackmann
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - C Uleer
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - B Aktas
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - C Schumacher
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - N Bangemann
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - C Lindner
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - S Kuemmel
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - M Clemens
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - J Potenberg
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - P Staib
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - A Kohls
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - E Pelz
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - RE Kates
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - R Wuerstlein
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - HH Kreipe
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| | - N Harbeck
- Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU
| |
Collapse
|
8
|
Kanti V, Nuwayhid R, Lindner J, Hillmann K, Bangemann N, Kleine-Tebbe A, Blume-Peytavi U, Garcia Bartels N. Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients. J Eur Acad Dermatol Venereol 2015; 30:112-8. [DOI: 10.1111/jdv.13396] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Accepted: 07/24/2015] [Indexed: 12/19/2022]
Affiliation(s)
- V. Kanti
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - R. Nuwayhid
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - J. Lindner
- Department of Gynecology and Obstetrics; Ostalb-Hospital; Aalen Germany
| | - K. Hillmann
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - N. Bangemann
- Interdisciplinary Breast Center; Charité -Universitätsmedizin Berlin; Berlin Germany
| | | | - U. Blume-Peytavi
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - N. Garcia Bartels
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
9
|
Kanti V, Nuwayhid R, Lindner J, Hillmann K, Stroux A, Bangemann N, Kleine-Tebbe A, Blume-Peytavi U, Garcia Bartels N. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study. Br J Dermatol 2014; 170:643-50. [DOI: 10.1111/bjd.12716] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2013] [Indexed: 12/11/2022]
Affiliation(s)
- V. Kanti
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - R. Nuwayhid
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - J. Lindner
- Department of Gynecology and Obstetrics; Ostalb-Hospital; Aalen Germany
| | - K. Hillmann
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - A. Stroux
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
- Department of Medical Statistics and Clinical Epidemiology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - N. Bangemann
- Interdisciplinary Breast Center; Charité - Universitätsmedizin Berlin; Berlin Germany
| | | | - U. Blume-Peytavi
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - N. Garcia Bartels
- Department of Dermatology and Allergy; Clinical Research Center for Hair and Skin Science; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
10
|
Feyer PC, Steiner U, Bangemann N, Kurz S, Rudolph C, Schelenz C, Jagota A. Evaluation of side effects in cancer patients during oncological care: A project of the supportive care group of the tumor center Berlin. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20715 Background: The therapeutic options in tumour treatment protocols include a maximum of tumour cell reduction and at the same time a minimum of side effects in order to secure a good quality of life for the cancer patient. Temporary side effects have been accepted in relation to the benefit risk calculation. A questionnaire for cancer patients was developed to improve the management of side effects of the cancer treatment, to optimize the patient-doctor communication and to register individual problems of the patient. Methods: Cancer patients received a questionnaire with 25 items and were asked for their problems during or after the last tumour specific treatment before having the consultation with the doctor. Gender, age, Karnofsky-index and treatment protocol were additional registered. During September 2007 until December 2007 a total of 272 questionnaires could be collected. The qualitative items have been evaluated with the contigens table method and the parameter free x2 test (Chi-Square-Test). Results: More than 50% of the patients documented additional important points influencing their well being. Nearly all of the evaluated patients had some tumour therapy specific side effects. The most pronounced problem was the physical exhaustion in 71% of the evaluated patients. More than 50% were influenced in their quality of life by more than normal fatigue since the start of their tumour specific therapy. Significant differences could be evaluated in relation to the age, diagnosis and tumour therapy with respect to the symptoms. Conclusions: The questionnaire was be found to be a good method to improve the communication between the patient and the doctor. It was easier to point out individual problems for the patient. The care givers can focus more precisely on important side effects of the tumour specific therapy in order to improve the quality of life of the treated patient. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. C. Feyer
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - U. Steiner
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - N. Bangemann
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - S. Kurz
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - C. Rudolph
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - C. Schelenz
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| | - A. Jagota
- Clinic of Radiooncology and Nuclear Medicine, Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Evangelische Lungenklinik Berlin, Berlin, Germany; DRK Kliniken Köpenick, Berlin, Germany; Subspecialized Practice Hematology/Oncology, Berlin, Germany; Tumour Centre Berlin e.V., Berlin, Germany
| |
Collapse
|
11
|
Schaller G, Bangemann N, Weber J, Kleine-Tebbe A, Beisler GK, Conrad B, Hindenburg HJ, Klare P, Ruhmland B, Hinke A. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.717] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Schaller
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - N. Bangemann
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - J. Weber
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - A. Kleine-Tebbe
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - G. K. Beisler
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - B. Conrad
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - H.-J. Hindenburg
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - P. Klare
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - B. Ruhmland
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| | - A. Hinke
- Marienhospital Herne der Ruhr Univ, Herne, Germany; Univklin Benjamin Franklin, Berlin, Germany; Kath. Krankenhaus Marienhospital, Herne, Germany; Virchow-Klinikum, Berlin, Germany; Praxis, Bad Wildbad, Germany; Elisabeth-Krankenhaus, Kassel, Germany; Praxis, Berlin, Germany; WiSP Research Institute, Langenfeld, Germany
| |
Collapse
|
12
|
Landt S, Bühler H, Vorsteher N, Evers K, Duvnjak B, Adam H, Bangemann N, Blohmer JU, Schaller G. Myocardial expression of HER2 and HER4 in anthracycline-pretreated breast cancer patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Landt
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - H. Bühler
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - N. Vorsteher
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - K. Evers
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - B. Duvnjak
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - H. Adam
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - N. Bangemann
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - J. U. Blohmer
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| | - G. Schaller
- Charité, Berlin, Germany; RUB, Bochum, Germany; Stadtspital Waid, Zürich, Switzerland
| |
Collapse
|
13
|
Vorsteher N, Bühler H, Duvnjak B, Evers K, Heine B, Landt S, Bangemann N, Schaller G. Expression patterns and prognostic significance of human epidermal growth factor receptors (HER family) in squamous cell carcinoma of the cervix. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - H. Bühler
- Charité, Berlin, Germany; RUB, Bochum, Germany
| | - B. Duvnjak
- Charité, Berlin, Germany; RUB, Bochum, Germany
| | - K. Evers
- Charité, Berlin, Germany; RUB, Bochum, Germany
| | - B. Heine
- Charité, Berlin, Germany; RUB, Bochum, Germany
| | - S. Landt
- Charité, Berlin, Germany; RUB, Bochum, Germany
| | | | - G. Schaller
- Charité, Berlin, Germany; RUB, Bochum, Germany
| |
Collapse
|
14
|
Drechsler I, Bangemann N, Schmid O, Hopp H, Hagen A. TRAP (Twin reversed arterial perfusion) Sequenz – ein Fallbericht. Z Geburtshilfe Neonatol 2004. [DOI: 10.1055/s-2003-818170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Buehler H, Becker C, Fuchs I, Bangemann N, Schaller G. The upregulation of cellular adhesion proteins following transfection of the keratin 18 gene into human breast cancer cells is accompanied by a dramatic decrease of invasion and metastasis in vitro and in vivo. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81207-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Schaller G, Bangemann N, Becker C, Bühler H, Opri F, Weitzel HK. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 1999; 125:520-4. [PMID: 10480346 DOI: 10.1007/s004320050311] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The HER2 protein, a member of the epidermal growth factor family, is encoded by the protooncogene c-erbB-2. Its overexpression, occurring in approximately one-third of all breast carcinomas, is associated with a poor prognosis. A humanized mouse antibody against HER2 has been developed by genetic engineering. Here an unspecific human IgG was connected to the recognizing mouse IgG fragment. The allergization typical for allogeneic antibodies does not take place in this context. The effectiveness of this antibody has been confirmed by two international prospective phase III trials that tested it alone and combined with chemotherapy. Both modes of application increased the response rates and the time to progression. Side-effects were rare except for a high rate of cardiac dysfunction when the antibody was combined with anthracyclines. The effectiveness and negligible side-effects of the chimeric antibody against HER2 (Herceptin) render it a valuable tool in the treatment of breast cancer.
Collapse
MESH Headings
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents/therapeutic use
- Breast Neoplasms/chemistry
- Breast Neoplasms/immunology
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/immunology
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Ductal, Breast/therapy
- Clinical Trials, Phase III as Topic
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Receptor, ErbB-2/analysis
- Receptor, ErbB-2/immunology
- Trastuzumab
- Treatment Outcome
- Up-Regulation
Collapse
Affiliation(s)
- G Schaller
- Department of Gynecology and Obstetrics, University Hospital Benjamin Franklin, Free University of Berlin, Germany
| | | | | | | | | | | |
Collapse
|